Your browser is no longer supported. Please, upgrade your browser.
DARE Dare Bioscience, Inc. daily Stock Chart
Dare Bioscience, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own38.91% Shs Outstand6.16M Perf Week-8.33%
Market Cap8.13M Forward P/E- EPS next Y- Insider Trans- Shs Float3.69M Perf Month-41.59%
Income-7.30M PEG- EPS next Q- Inst Own17.70% Short Float4.09% Perf Quarter-50.56%
Sales0.80M P/S10.16 EPS this Y8.90% Inst Trans-0.55% Short Ratio0.50 Perf Half Y-50.75%
Book/sh4.50 P/B0.29 EPS next Y- ROA-73.50% Target Price15.00 Perf Year-89.61%
Cash/sh1.38 P/C0.96 EPS next 5Y- ROE-104.00% 52W Range1.35 - 35.80 Perf YTD-39.00%
Dividend- P/FCF- EPS past 5Y-0.70% ROI-307.10% 52W High-96.31% Beta2.62
Dividend %- Quick Ratio12.40 Sales past 5Y20.20% Gross Margin- 52W Low-2.22% ATR0.27
Employees19 Current Ratio12.40 Sales Q/Q- Oper. Margin- RSI (14)35.95 Volatility9.37% 11.17%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.98 Prev Close1.37
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume303.66K Price1.32
Recom1.00 SMA20-32.19% SMA50-39.98% SMA200-59.81% Volume293,313 Change-3.65%
Feb-15-18 11:06AM  Daré Bioscience, Inc. Announces Effective License and Collaboration Agreement for Topical Sildenafil for Female Sexual Arousal Disorder GlobeNewswire
Feb-13-18 09:18AM  Daré Bioscience, Inc. to raise approximately $10.25 million GlobeNewswire -39.78%
08:30AM  Todays Research Reports on Trending Tickers: Dare Bioscience and MannKind ACCESSWIRE
Feb-12-18 08:57PM  Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire +50.00%
08:00AM  Daré Bioscience, Inc. Enters into License and Collaboration Agreement for a Product with the Potential to Receive the First FDA Approval for Female Sexual Arousal Disorder GlobeNewswire
Feb-06-18 08:00AM  Daré Bioscience, Inc. to Present at the 2018 BIO CEO & Investor Conference GlobeNewswire +7.37%
Jan-10-18 09:01AM  Sabrina Martucci Johnson Joins Aethlon Medical's Board of Directors PR Newswire
Dec-08-17 07:03PM  Who Are The Major Shareholders Of Daré Bioscience Inc (DARE)? Simply Wall St. +9.17%
Dec-04-17 08:00AM  Daré Bioscience, Inc. to Present at the LD Micro 10th Annual Main Event Conference GlobeNewswire
Nov-30-17 01:05PM  With An ROE Of 177.59%, Has Daré Bioscience Incs (DARE) Management Done A Good Job? Simply Wall St.
Oct-20-17 09:56AM  Daré Bioscience Inc (DARE): Is Healthcare Attractive Relative To NasdaqCM Peers? Simply Wall St.
Oct-10-17 08:30AM  Daré Bioscience, Inc. to Present at the 2017 BIO Investor Forum GlobeNewswire
Sep-07-17 08:30AM  Daré Bioscience, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-30-17 08:30AM  Daré Bioscience, Inc. to Present at the Liolios 6th Annual Gateway Conference GlobeNewswire
Aug-15-17 08:30AM  Daré Bioscience, Inc. CEO Featured in San Diego Business Journal Article on Women Founders GlobeNewswire
Dare Bioscience, Inc. develops and commercializes product for women's reproductive health, Ovaprene. The company was incorporated in 2015 and is based in La Jolla, California.